Mohamed Shanavas - Concepedia

Author

Mohamed Shanavas

Princess Margaret Cancer Centre ORCID

Also Known As

M Shanavas, M. Shanavas, Mohamed Shanavas

Publications

358

Citations

H-Index

Concepts

All Affiliations

Princess Margaret Cancer Centre University of Toronto

About

Mohamed Shanavas is an author at Princess Margaret Cancer Centre specializing in hematology, immunology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	284
2	Immunology	6	6	284
3	Blood Transplantation	4	4	213
4	Marrow Transplantation	4	4	213
5	Cellular Therapies	1	1	32

Mohamed Shanavas

Publications

320

Citations

H-Index

Page 1

	Year	Citations
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors Mohamed Shanavas, Uday Popat, Laura C. Michaelis, Biology of Blood and Marrow Transplantation Antifibrotic TherapyImmunologyPathologyJanus Kinase 1/2Immunotherapy	2015	142
The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD Jieun Uhm, Nada Hamad, Fotios V. Michelis, Bone Marrow Transplantation Viral PersistenceCmv ViremiaHematologyImmunologyPathology	2014	59
Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning Mohamed Shanavas, Hans A. Messner, Eshetu G. Atenafu, Bone Marrow Transplantation Hematological MalignancyCell TherapyTransplantationMarrow TransplantationHematology	2014	32
A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation Mohamed Shanavas, Hans A. Messner, Suzanne Kamel‐Reid, Clinical Lymphoma Myeloma & Leukemia TransplantationMarrow TransplantationMedicineTransplantation MedicineImmunology	2013	22
Incidence, Risk Factors, and Long-Term Outcomes of Sclerotic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation Jieun Uhm, Nada Hamad, Elizabeth Shin, Biology of Blood and Marrow Transplantation	2014	20
Mycophenolate‐based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative‐related donor stem cell transplantation Nada Hamad, Mohamed Shanavas, Fotios V. Michelis, American Journal of Hematology Transplant RejectionTransplantationMarrow TransplantationGvhd ProphylaxisCmv Viremia	2015	17
Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma Karthik Nath, Soi Cheng Law, Muhammed B. Sabdia, Blood Advances	2021	16
Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis Justyna Bartoszko, Tony Panzarella, Anthea Lau, Clinical Lymphoma Myeloma & Leukemia Hematological MalignancyMyeloproliferative Neoplasm-associated MyelofibrosisNatural HistoryImmunologyHematology	2015	12

Page 1